Gynecological and sexual aftereffects following rectal cancer treatment
Official title: Evaluation of Gynecological and Sexual Sequelae in Patients Treated for Rectal Cancer
Run by University Hospital, Rouen · NCT07389863 · Data updated 2026-11-12
This work will test whether gynecological anatomical changes after rectal cancer treatment are linked to ongoing sexual problems in women aged 18–60 who are in remission.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 60 Years |
| Sex | All |
| Enrollment | 15 (estimated) |
| Sponsor | University Hospital, Rouen Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Rouen) |
| Status | Recruiting |
| Started | February 9, 2026 |
| Main results expected | May 1, 2027 |
| Study ends | September 1, 2027 |
| Registry record updated | May 5, 2026 |
| Trial ID | NCT07389863 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Women aged 18–60 treated for rectal cancer between 2020 and 2025 who are in remission, were sexually active before treatment, and completed the required questionnaires are ideal candidates.
✕Probably not a fit
Women with active cancer or ongoing chemotherapy, those who are pregnant, have had extensive prior gynecological surgery, cognitive or language barriers, or lack social security coverage are ineligible and unlikely to benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study enrolling women treated for rectal cancer between 2020 and 2025 who are currently in remission. Participants who were sexually active before treatment and completed treatment questionnaires will have clinical gynecological information and patient-reported sexual function data reviewed to characterize anatomical and sexual sequelae. The study focuses on effects related to surgery and pelvic radiotherapy such as nerve injury, fibrosis, dyspareunia, and vaginal dryness, and does not involve any experimental treatments. Results are intended to improve detection, timing, and management of gynecological and sexual complications after rectal cancer.
Why it matters
Potential benefit: If successful, the findings could enable earlier detection and better management of gynecological and sexual problems after rectal cancer, improving long-term quality of life.
How similar studies have gone: Prior research has documented sexual dysfunction after pelvic cancer treatments, but comprehensive clinical data specifically quantifying gynecological anatomical sequelae after rectal cancer remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women aged 18 to 60 at the time of diagnosis * Having been treated for rectal cancer between 2020 and 2025 * Cancer in remission * Having been sexually active before receiving treatment for their rectal cancer * Having completed the various questionnaires during their treatment Exclusion Criteria: * Inability to complete questionnaires (cognitive impairment, language barrier) * Pregnant women * Women with active cancer and/or undergoing chemotherapy * Women with a history of extensive gynecological surgery * Individuals deprived of their liberty by an administrative or judicial decision, or individuals under legal protection/guardianship or curatorship * Individuals without social security coverage
Where it's running
-
Service de Chirurgie Digestive
Rouen, France Recruiting
Study contacts
- Principal investigator: Pauline PL LUDWIG, Doctor junior — University Rouen Hospital
- Study coordinator: Nabila NL LAAJAIL, Director
- Email: Secretariat.DRC@chu-rouen.fr
- Phone: 02 32 88 82 65
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
NeoCSR-Omics: CAPOX and Serplulimab Before or After Short-Course RT in Locally Advanced Rectal Cancer
This trial tests whether giving CAPOX chemotherapy with the PD-1 blocker serplulimab before or after short-course radiotherapy helps people with locally advanced rectal cancer achieve complete clinical or pathological responses.
-
PPISR for low- to mid-rectal cancer with anus-sparing aim
This study tests whether Precision Partial Intersphincteric Resection can be safely used to remove certain rectal cancers while preserving the anus.
-
BT-001 plus pembrolizumab for localized pMMR rectal cancer
This early-phase trial tests whether adding the oncolytic virus BT-001 to pembrolizumab is safe and tolerable for adults with localized pMMR rectal cancer prior to definitive surgery.
-
Transanal vs Robotic Total Mesorectal Excision for Low Rectal Cancer
This study tests whether taTME or robot-assisted TME works better for low rectal cancer patients and whether one method leads to fewer complications or conversions.
-
Selective completion total mesorectal excision guided by intra-operative frozen pathology after local excision for low rectal cancer
This trial tests whether using an immediate frozen-pathology result after local excision to decide if a full total mesorectal excision is needed can keep cancer controlled for adults with low rectal cancer who had a near-complete or small residual response to preoperative chemoradiotherapy.
-
Radiotherapy Plus CAPOX and Iparomlimab and Tuvonralimab as Neoadjuvant Therapy for Locally Advanced Rectal Cancer
This trial tests whether adding immunotherapy with chemotherapy and radiotherapy before surgery can improve how well locally advanced rectal cancer responds.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.